IRONWOOD PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Increase (Decrease) in Accounts Receivable of $65.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $6.89M, a 85.15% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $59.10M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$73.62M, a 1395.27% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $34.19M, a 88.96% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was -$35.15M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was -$47.24M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$924.00K.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$7.99M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $65.99M 10-Q · filed 2026-08-06 | -$7.64M derived: sum of 3 quarters · filed 2026-08-06 | $26.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $59.10M 10-Q · filed 2026-05-07 | -$14.53M derived: sum of 2 quarters · filed 2026-05-07 | $19.67M derived: sum of 3 quarters · filed 2026-05-07 | $66.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$73.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$39.43M derived: sum of 2 quarters · filed 2026-02-26 | $6.97M derived: sum of 3 quarters · filed 2026-08-06 | -$35.15M 10-K · filed 2026-02-26 |
| 2025-09-30 | $34.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $80.59M derived: sum of 2 quarters · filed 2026-08-06 | $38.48M 10-Q · filed 2025-11-10 | $44.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $46.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.28M 10-Q · filed 2026-08-06 | $9.97M derived: sum of 3 quarters · filed 2026-08-06 | $28.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$42.12M 10-Q · filed 2026-05-07 | -$36.43M derived: sum of 2 quarters · filed 2026-05-07 | -$18.34M derived: sum of 3 quarters · filed 2026-05-07 | -$32.25M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.78M derived: sum of 2 quarters · filed 2026-02-26 | $9.87M derived: sum of 3 quarters · filed 2026-02-26 | -$47.24M 10-K · filed 2026-02-26 |
| 2024-09-30 | $18.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.19M derived: sum of 2 quarters · filed 2025-11-10 | -$52.92M 10-Q · filed 2025-11-10 | -$48.34M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$13.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$71.02M 10-Q · filed 2025-08-11 | -$66.44M derived: sum of 3 quarters · filed 2025-08-11 | -$60.88M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$57.11M 10-Q · filed 2025-05-12 | -$52.53M derived: sum of 2 quarters · filed 2025-05-12 | -$46.97M derived: sum of 3 quarters · filed 2025-05-12 | -$43.73M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $10.13M derived: sum of 2 quarters · filed 2025-03-31 | $13.37M derived: sum of 3 quarters · filed 2025-03-31 | -$924.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $5.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $8.80M derived: sum of 2 quarters · filed 2024-11-07 | -$5.50M 10-Q · filed 2024-11-07 | -$6.44M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$11.06M 10-Q · filed 2024-08-08 | -$11.99M derived: sum of 3 quarters · filed 2025-03-31 | $2.34M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | -$14.30M 10-Q · filed 2024-05-09 | -$15.23M derived: sum of 2 quarters · filed 2025-03-31 | -$897.00K derived: sum of 3 quarters · filed 2025-03-31 | -$3.91M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | -$937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.40M derived: sum of 2 quarters · filed 2025-03-31 | $10.39M derived: sum of 3 quarters · filed 2025-03-31 | -$7.99M 10-K · filed 2025-03-31 |
| 2022-09-30 | $14.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $11.33M derived: sum of 2 quarters · filed 2023-11-09 | -$7.06M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$21.39M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$18.38M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$7.71M 10-K · filed 2024-02-16 | |||
| 2012-06-30 | $2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $1.81M 10-Q · filed 2012-08-07 | $1.73M derived: sum of 3 quarters · filed 2012-08-07 | -$161.00K derived: sum of 4 quarters · filed 2012-08-07 |
| 2012-03-31 | -$543.00K 10-Q · filed 2012-05-10 | -$632.00K derived: sum of 2 quarters · filed 2012-05-10 | -$2.52M derived: sum of 3 quarters · filed 2012-05-10 | -$4.08M derived: sum of 4 quarters · filed 2012-08-07 |
| 2011-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$1.98M derived: sum of 2 quarters · filed 2012-02-29 | -$3.53M derived: sum of 3 quarters · filed 2012-08-07 | -$2.24M 10-K · filed 2012-02-29 |
| 2011-09-30 | -$1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$3.44M derived: sum of 2 quarters · filed 2012-08-07 | -$2.15M 10-Q · filed 2011-11-09 | -$4.31M derived: sum of 4 quarters · filed 2012-08-07 |
| 2011-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$268.00K 10-Q · filed 2012-08-07 | -$2.42M derived: sum of 3 quarters · filed 2012-08-07 | -$1.97M derived: sum of 4 quarters · filed 2012-08-07 |
| 2011-03-31 | $1.29M 10-Q · filed 2012-05-10 | -$865.00K derived: sum of 2 quarters · filed 2012-05-10 | -$414.00K derived: sum of 3 quarters · filed 2012-05-10 | |
| 2010-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$1.70M derived: sum of 2 quarters · filed 2012-02-29 | -$2.32M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$170.00K 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$621.00K 10-Q · filed 2011-08-12 | |||
| 2009-12-31 | $648.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |